Cellectis SA (CLLS)
3.67
+0.17
(+4.86%)
USD |
NASDAQ |
May 26, 16:00
3.63
-0.04
(-1.09%)
After-Hours: 20:00
Cellectis Cash from Investing (Quarterly) : -6.187M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| DBV Technologies SA | -0.3011M |
| Akari Therapeutics Plc | 0.00 |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -0.1037M |
| Autolus Therapeutics Plc | 95.99M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.56M |
| Cash from Financing (Quarterly) | -4.826M |
| Free Cash Flow | -41.80M |
| Free Cash Flow Per Share (Quarterly) | -0.1574 |
| Free Cash Flow to Equity (Quarterly) | -4.528M |
| Free Cash Flow to Firm (Quarterly) | -13.76M |
| Free Cash Flow Yield | -11.31% |